Mayday University Hospital awarded 3 stars in NHS performance rating

Posted:
4
August 2005

Unit At Mayday

We are delighted to announce that Mayday University Hospital NHS Trust was recently issued an annual performance rating of 3 stars, which places them in the top 28% of Trusts in the UK. This is the highest rating available under the Healthcare Commission rating scheme.The performance rating reports are designed to review the key factors the Trusts need to achieve to deliver a better service to patients. This includes Patient Focus, Clinical Focus, Capacity and Capability Focus, Access to Quality Services, Improving Health and Services Provision. Overall, the Healthcare Commission report concluded that Mayday Hospital is delivering in each of these areas.Dr Jörg Täubel, Managing Director of Richmond Pharmacology, commented: “We have been working closely with the Trust over the past 18 months to facilitate the move of our second unit to Mayday hospital. Throughout this period of time I have been consistently impressed with the quality I experienced when working with the Trust. I am very pleased that this standard has been recognized by the Healthcare Commission. It's reassuring to conduct our trials within such a well managed, acute setting.”Richmond opened the new unit within Mayday University Hospital in May 2005.To view the Healthcare Commission report on Mayday click here.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more